SABS vs. GOSS
SABS (SAB Biotherapeutics, Inc.) and GOSS (Gossamer Bio, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, SABS returned -47.61%/yr vs -54.26%/yr for GOSS. At a 0.12 correlation, their price movements are largely independent.
Performance
SABS vs. GOSS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SABS achieves a 5.08% return, which is significantly higher than GOSS's -94.70% return.
SABS
- 1D
- -1.75%
- 1M
- 0.77%
- YTD
- 5.08%
- 6M
- 2.34%
- 1Y
- 119.55%
- 3Y*
- -21.42%
- 5Y*
- -47.61%
- 10Y*
- —
GOSS
- 1D
- -2.26%
- 1M
- -21.85%
- YTD
- -94.70%
- 6M
- -95.64%
- 1Y
- -88.60%
- 3Y*
- -50.45%
- 5Y*
- -54.26%
- 10Y*
- —
SABS vs. GOSS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
SABS SAB Biotherapeutics, Inc. | 5.08% | -1.43% | -44.81% | 16.55% | -92.45% | -23.58% |
GOSS Gossamer Bio, Inc. | -94.70% | 242.69% | -0.87% | -57.95% | -80.81% | 4.92% |
Correlation
The correlation between SABS and GOSS is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.13 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.12 |
Correlation (All Time) Calculated using the full available price history since Feb 9, 2021 | 0.12 |
Fundamentals
SABS:
$210.49M
GOSS:
$38.45M
SABS:
-$0.01
GOSS:
-$0.79
SABS:
$0.00
GOSS:
$55.54M
SABS:
-$2.35M
GOSS:
$38.36M
SABS:
$994.59K
GOSS:
-$171.46M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SABS vs. GOSS — Risk / Return Rank
SABS
GOSS
SABS vs. GOSS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SAB Biotherapeutics, Inc. (SABS) and Gossamer Bio, Inc. (GOSS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SABS | GOSS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.09 | ||
| Sortino ratioReturn per unit of downside risk | +3.07 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 0.88 | +0.41 |
| Calmar ratioReturn relative to maximum drawdown | 3.56 | -0.93 | +4.48 |
| Martin ratioReturn relative to average drawdown | 7.65 | -1.60 | +9.25 |
Loading charts...
Drawdowns
SABS vs. GOSS - Drawdown Comparison
The maximum SABS drawdown since its inception was -99.01%, roughly equal to the maximum GOSS drawdown of -99.42%. Use the drawdown chart below to compare losses from any high point for SABS and GOSS.
Loading charts...
Drawdown Indicators
| SABS | GOSS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.01% | -99.42% | +0.41% |
Max Drawdown (1Y)Largest decline over 1 year | -33.80% | -95.88% | +62.08% |
Max Drawdown (3Y)Largest decline over 3 years | -88.96% | -95.88% | +6.92% |
Max Drawdown (5Y)Largest decline over 5 years | -99.01% | -98.95% | -0.06% |
Current DrawdownCurrent decline from peak | -96.50% | -99.39% | +2.89% |
Average DrawdownAverage peak-to-trough decline | -78.14% | -71.53% | -6.61% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.69% | 55.33% | -39.64% |
Volatility
SABS vs. GOSS - Volatility Comparison
The current volatility for SAB Biotherapeutics, Inc. (SABS) is 21.76%, while Gossamer Bio, Inc. (GOSS) has a volatility of 29.87%. This indicates that SABS experiences smaller price fluctuations and is considered to be less risky than GOSS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SABS | GOSS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 21.76% | 29.87% | -8.11% |
Volatility (6M)Calculated over the trailing 6-month period | 45.35% | 182.70% | -137.35% |
Volatility (1Y)Calculated over the trailing 1-year period | 85.65% | 130.16% | -44.51% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 112.38% | 103.47% | +8.91% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 108.46% | 93.61% | +14.85% |
Dividends
SABS vs. GOSS - Dividend Comparison
Neither SABS nor GOSS has paid dividends to shareholders.
Financials
SABS vs. GOSS - Financials Comparison
This section allows you to compare key financial metrics between SAB Biotherapeutics, Inc. and Gossamer Bio, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
SABS and GOSS have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GOSS has higher volatility (29.87%) compared to SABS (21.76%). In terms of maximum drawdown, SABS dropped -99.01% vs GOSS's -99.42%.
SABS currently has the higher Sharpe Ratio (1.41 vs -0.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SABS and GOSS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer